NDA 209863 · Antares Pharma INC
Xyosted (Autoinjector)
Testosterone Enanthate · Subcutaneous
Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 28, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
47
9 Phase 3, 5 recruiting
FAERS reports
1,642
475 serious, 27 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2025.
XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established ( 1 ). Safety and efficacy of XYOSTED in males less than 18 years old have not been established ( 1 , 8.4 ).
Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone,...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 100MG/0.5ML (100MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 50MG/0.5ML (50MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- XYOSTED (AUTOINJECTOR) · TESTOSTERONE ENANTHATE 75MG/0.5ML (75MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Testosterone Enanthate" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismPivotal-lookingCompleted
Lipocine Inc.Industry
NCT02081300 · 315 participants · Start Feb 2014 · Primary completion May 2015
Drug: Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 % · For: Male Hypogonadism
- Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI TrialPivotal-lookingNot yet recruiting
VA Office of Research and DevelopmentFederal agency
NCT07742553 · 300 participants (planned) · Start Oct 1, 2027 · Primary completion Sep 30, 2031
Drug: testosterone cypionate; finasteride and 2 more · For: Spinal Cord Injury; Spinal Cord Injuries; Injuries, Spinal Cord and 11 more
Sites: Aurora, Colorado; Gainesville, Florida; Tampa, Florida · 4 sites in all
- Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide ResistancePivotal-lookingCompleted
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT02286921 · 222 participants · Start Jan 2015 · Primary completion Oct 26, 2018
Drug: Testosterone cypionate; Enzalutamide and 1 more · For: Castration Resistant Metastatic Prostate Cancer
Sites: Birmingham, Alabama; Duarte, California; Aurora, Colorado · 17 sites in all
- The Role of 5-alpha Reductase in Mediating Testosterone ActionsPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00493987 · 184 participants (planned) · Start Nov 2002 · Primary completion Dec 2009
Drug: Testosterone Enanthate; Dutasteride · For: Healthy
Sites: Boston, Massachusetts
- The Effect of 5-Alpha Reductase on Testosterone in MenPivotal-lookingStatus unknown
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00070733 · 184 participants · Start Aug 2003
Drug: testosterone enanthate; duastride · For: Sex Disorders
Sites: Los Angeles, California
- Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionPivotal-lookingRecruiting
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT04363164 · 150 participants (planned) · Start Aug 19, 2020 · Primary completion Jul 2027
Drug: Testosterone cypionate; Enzalutamide and 1 more · For: Castration Resistant Metastatic Prostate Cancer
Sites: San Diego, California; Baltimore, Maryland; Boston, Massachusetts · 6 sites in all
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT04971447 · 136 participants (planned) · Start Aug 2022 · Primary completion Sep 2023
Drug: gender affirming hormonal treatment in transgender men; gender affirming hormonal treatment in transgender women · For: Transgenderism
- Oral Testosterone for the Treatment of HypogonadismPivotal-lookingCompleted
TesoRx Pharma, LLCIndustry
NCT01717768 · 130 participants · Start Oct 2012 · Primary completion Aug 2014
Drug: TSX-002 · For: Hypogonadism
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue354
- injection site pain160
- injection site haemorrhage142
- drug ineffective111
- off label use100
- injection site mass61
- fatigue57
- injection site bruising56
- accidental exposure to product53
- product dose omission52
- product use in unapproved indication51
- injection site erythema41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 10 |
| 2009 | 17 |
| 2010 | 10 |
| 2011 | 6 |
| 2012 | 15 |
| 2013 | 16 |
| 2014 | 25 |
| 2015 | 55 |
| 2016 | 39 |
| 2017 | 26 |
| 2018 | 31 |
| 2019 | 80 |
| 2020 | 198 |
| 2021 | 205 |
| 2022 | 212 |
| 2023 | 240 |
| 2024 | 53 |
| 2025 | 242 |
| 2026 | 142 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Testosterone dose-response relationships in healthy young men.
Bhasin S, Woodhouse L, Casaburi R, et al. · Am J Physiol Endocrinol Metab 2001 · Clinical Trial, Randomized Controlled Trial
- The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.
Bhasin S, Storer TW, Berman N, et al. · N Engl J Med 1996 · Clinical Trial, Randomized Controlled Trial
- Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.
Vandekerckhove P, Lilford R, Vail A, et al. · Cochrane Database Syst Rev 2000 · Systematic Review
- The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials.
Nackeeran S, Kohn T, Gonzalez D, et al. · J Urol 2022 · Comparative Study, Systematic Review
- A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males.
Sinju S, Sridhar S, Sreenivasan P, et al. · Clin Endocrinol (Oxf) 2025 · Randomized Controlled Trial, Comparative Study
- WITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia.
Vandekerckhove P, Lilford R, Vail A, et al. · Cochrane Database Syst Rev 2007 · Systematic Review
Sponsor: Antares Pharma INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.